A. Cseh

916 total citations
39 papers, 604 citations indexed

About

A. Cseh is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, A. Cseh has authored 39 papers receiving a total of 604 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 33 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in A. Cseh's work include Lung Cancer Treatments and Mutations (37 papers), HER2/EGFR in Cancer Research (12 papers) and Colorectal Cancer Treatments and Studies (11 papers). A. Cseh is often cited by papers focused on Lung Cancer Treatments and Mutations (37 papers), HER2/EGFR in Cancer Research (12 papers) and Colorectal Cancer Treatments and Studies (11 papers). A. Cseh collaborates with scholars based in Austria, United States and Germany. A. Cseh's co-authors include Flavio Solca, Maximilian J. Hochmair, Petr Kavan, David A. Reardon, Helmut Prosch, Sophia Schwab, Wolfgang Hilbe, Martin Filipits, Otto C. Burghuber and Anna Buder and has published in prestigious journals such as Annals of Oncology, Oncotarget and The Oncologist.

In The Last Decade

A. Cseh

36 papers receiving 596 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Cseh Austria	12	401	393	176	163	128	39	604
Lucia Trandafir Switzerland	11	272 0.7×	247 0.6×	280 1.6×	85 0.5×	73 0.6×	22	634
Jens Enoksson Sweden	6	246 0.6×	353 0.9×	532 3.0×	176 1.1×	142 1.1×	8	763
Anna Wurtz United States	11	296 0.7×	278 0.7×	266 1.5×	127 0.8×	33 0.3×	19	595
Mary Ann Melnick United States	9	676 1.7×	586 1.5×	491 2.8×	261 1.6×	39 0.3×	14	977
Jessica Sohl United States	8	447 1.1×	607 1.5×	133 0.8×	287 1.8×	119 0.9×	17	819
Simona Rizzato Italy	10	148 0.4×	139 0.4×	128 0.7×	133 0.8×	300 2.3×	24	448
Lyudmila Bazhenova United States	16	563 1.4×	534 1.4×	270 1.5×	114 0.7×	30 0.2×	83	749
Molly Catherine Hardebeck United States	9	543 1.4×	554 1.4×	327 1.9×	271 1.7×	194 1.5×	13	912
Francois J. Geoffroy United States	9	180 0.4×	285 0.7×	204 1.2×	109 0.7×	234 1.8×	18	571
Bernhard Heinrich Germany	14	187 0.5×	439 1.1×	160 0.9×	66 0.4×	52 0.4×	36	630

Countries citing papers authored by A. Cseh

Since Specialization

Citations

This map shows the geographic impact of A. Cseh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Cseh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Cseh more than expected).

Fields of papers citing papers by A. Cseh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Cseh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Cseh. The network helps show where A. Cseh may publish in the future.

Co-authorship network of co-authors of A. Cseh

This figure shows the co-authorship network connecting the top 25 collaborators of A. Cseh. A scholar is included among the top collaborators of A. Cseh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Cseh. A. Cseh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhao, Jun, Hua Bai, Xin Wang, et al.. (2022). Biomarker Subset Analysis of a Phase IIIb, Open-Label Study of Afatinib in EGFR Tyrosine Kinase Inhibitor-Naive Patients with EGFR m+ Non-Small-Cell Lung Cancer. Future Oncology. 18(12). 1485–1497. 1 indexed citations

Owen, Scott, Jad Alshami, Marie‐Christine Guiot, et al.. (2022). Genomic Analysis of Tumors from Patients with Glioblastoma with Long-Term Response to Afatinib. OncoTargets and Therapy. Volume 15. 367–380. 2 indexed citations

Passaro, Antonio, Filippo de Marinis, Hai‐Yan Tu, et al.. (2021). Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. Frontiers in Oncology. 11. 709877–709877. 12 indexed citations

Subramanian, Janakiraman, et al.. (2021). MO01.14 Real-World Effectiveness and Safety of Afatinib Following Immunotherapy (IO) in the Treatment of Metastatic, Squamous Cell/Mixed Histology Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Trial in the US. Journal of Thoracic Oncology. 16(1). S21–S22.

Kim, Edward S., et al.. (2021). Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA. Clinical Lung Cancer. 22(4). 292–300.e1. 4 indexed citations

Zöchbauer‐Müller, Sabine, Helmut Prosch, A. Cseh, et al.. (2021). Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation. Frontiers in Oncology. 10. 593852–593852. 12 indexed citations

Goss, Glenwood, Manuel Cobo, Shun Lü, et al.. (2021). Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. EClinicalMedicine. 37. 100940–100940. 9 indexed citations

Saran, Frank, Liam Welsh, Allan James, et al.. (2021). Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial. Journal of Neuro-Oncology. 155(3). 307–317. 12 indexed citations

Gajra, Ajeet, et al.. (2020). 1956P A real-world feasibility study of patients with solid tumours harbouring NRG1 gene fusions. Annals of Oncology. 31. S1102–S1102. 2 indexed citations

10.

Marinis, Filippo de, К. К. Лактионов, Artem Poltoratskiy, et al.. (2020). Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study. Lung Cancer. 152. 127–134. 20 indexed citations

11.

Weinberg, Benjamin A., Daniel J. Renouf, Howard J. Lim, et al.. (2019). NRG1-fusion positive gastrointestinal tumours: afatinib as a novel potential treatment option. Annals of Oncology. 30. iv80–iv80. 3 indexed citations

12.

Duruisseaux, M., Janessa Laskin, Khaled Tolba, et al.. (2019). P1.14-25 Targeting NRG1-Fusions in Lung Adenocarcinoma: Afatinib as a Novel Potential Treatment Strategy. Journal of Thoracic Oncology. 14(10). S563–S563. 2 indexed citations

13.

Thongprasert, Sumitra, et al.. (2018). 157P Second-line afatinib for patients with locally advanced or metastatic NSCLC harbouring common EGFR mutations: A phase IV study. Journal of Thoracic Oncology. 13(4). S94–S94.

14.

Chang, Gee‐Chen, Chun‐Ming Tsai, Jin‐Yuan Shih, et al.. (2018). P1.01-11 Named Patient Use Program for Afatinib in Advanced NSCLC with Progression on Prior Therapy: Experience from Asian Centers. Journal of Thoracic Oncology. 13(10). S463–S463. 2 indexed citations

15.

Lü, Shun, Wěi Li, Caicun Zhou, et al.. (2018). Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung. OncoTargets and Therapy. Volume 11. 8565–8573. 7 indexed citations

16.

Kim, Edward S., Balázs Halmos, Taral Patel, et al.. (2017). Efficacy and Safety Results of the Afatinib Expanded Access Program. Oncology and Therapy. 5(1). 103–110. 4 indexed citations

17.

Thongprasert, Sumitra, Aurelia Alexandru, Michael Schenker, et al.. (2015). 477TiP Phase IV study of afatinib as second-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations (Del19 and/or L858R). Annals of Oncology. 26. ix125–ix125. 1 indexed citations

18.

Alshami, Jad, Marie‐Christine Guiot, Scott Owen, et al.. (2015). Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: A case report. Oncotarget. 6(32). 34030–34037. 16 indexed citations

19.

Cappuzzo, Federico, Giovanna Finocchiaro, Francesco Grossi, et al.. (2014). Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 10(4). 665–672. 22 indexed citations

20.

Reardon, David A., Burt Nabors, Warren Mason, et al.. (2014). Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro-Oncology. 17(3). 430–9. 134 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact